---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000014"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:09:42.676915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Summit FY25 GAAP net loss $1.08B, BLA accepted with PDUFA Nov 14, HARMONi-3 interim PFS Q2 2026

## Summary
- GAAP net loss $1,079.6M ($1.44/sh) vs $221.3M ($0.31/sh) FY24; non-GAAP net loss $347.2M ($0.46/sh).
- Cash and equivalents $713.4M at Dec 31, 2025, up from $412.3M at Dec 31, 2024.
- FDA accepted BLA for ivonescimab+chemo in EGFR-mutated NSCLC; PDUFA goal date Nov 14, 2026.
- HARMONi-3 squamous cohort screening complete; interim PFS analysis planned Q2 2026; final PFS H2 2026.
- New Phase III ILLUMINE study (GORTEC) in HNSCC to initiate; first patient expected early Q2 2026.

## SEC filing metadata
- accession: 0001599298-26-000014
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/0001599298-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/smmt-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000014
- JSON: https://secwatch.observer/filing/0001599298-26-000014.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.